Establishment and validation of high-throughput methods for biomarker development in SCA1/2 and 3
- Conditions
- G00-G99Diseases of the nervous system
- Registration Number
- DRKS00020219
- Lead Sponsor
- niversitätsklinikum Tübingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
SCA3 disease
Exclusion Criteria
No study consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measuring if disease protein itself is a potential molecular marker for SCA3 disease progression.<br>Primary outcome: ataxin-3 protein as progression marker: Yes/no
- Secondary Outcome Measures
Name Time Method secondary aims are clinincal data (like age at onset, disease duration, clinical scores like SARA, INAS)<br><br>No endpoints are defined because each measurement points stands alone.